Pharmaceuticals
Vanda Pharmaceuticals Rejects Unsolicited Acquisition Proposals from Future Pak
Board Determines Offers Undervalue Company's Robust Growth Prospects Vanda Pharmaceuticals (VNDA) has confirmed receiving multiple unsolicited acquisition proposals from Future...
Palisade Bio Reports Promising Results for UC Treatment PALI-2108
Successful Analysis Demonstrates Effective Bioactivation of Colon-Specific PDE4 Inhibitor Prodrug Palisade Bio (PALI), a biopharmaceutical firm dedicated to advancing therapies...
PaxMedica Completes Milestone for Suramin IV Formulation, Nears FDA Submission
Biopharmaceutical Company Advances Potential Treatment for Fatal Tropical Disease and Autism Spectrum Disorder PaxMedica (PXMD) has achieved a significant milestone...
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in $4.9 Billion Deal
Acquisition Strengthens Vertex's Position in Immunotherapy and Renal Disease Treatment Vertex Pharmaceuticals (VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN)...
Advancing Addiction Treatment: Adial Pharmaceuticals’ AD04 Shows Promise in Clinical Study
Peer-Reviewed Article Highlights Safety and Efficacy of Low-Dose Ondansetron in Treating Alcohol Use Disorder Adial Pharmaceuticals (ADIL), a pioneer in...
Fanapt Receives FDA Approval for Bipolar I Disorder Treatment
Vanda Pharmaceuticals Expands Fanapt Franchise with Novel Indication Vanda Pharmaceuticals (VNDA) has announced a significant milestone as the U.S. Food...
AbbVie to Acquire Landos Biopharma: Advancing Novel Oral Therapies for Autoimmune Diseases
AbbVie's Acquisition of Landos Marks a Strategic Move in Autoimmune Disease Treatment Development AbbVie Inc. (ABBV) has announced a definitive...
IGC Pharma’s IGC-AD1 Shows Promising Results in Alzheimer’s Agitation Trial
Interim Analysis Reveals Statistically Significant Reduction in Agitation Levels IGC Pharma (IGC) has unveiled encouraging findings from its ongoing Phase...
FDA Delays Decision on Eli Lilly’s Alzheimer’s Drug, Donanemab
Eli Lilly's anticipation for the Food and Drug Administration's approval decision regarding its Alzheimer's treatment, donanemab, faces a setback as...
AbbVie Plans $13 Billion Bond Sale for Acquisitions
According to Bloomberg News sources familiar with the matter, AbbVie is gearing up to sell a minimum of $13 billion...
